Clinical trial NCT05540717: Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
Official title: A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen Exposure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Seasonal Allergic Rhinitis
Rhinoconjunctivitis
Lead sponsor: Allergy Therapeutics
Sponsor class: INDUSTRY
First posted: 2022-09-15
Enrollment: 555
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass.

The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600 SU. This will be determined through the measurements of the effect of PQ Grass on the symptoms of seasonal allergic rhinitis (SAR)/rhinoconjunctivitis and the use of relief medications to control these symptoms during the peak grass pollen season (GPS).

Detailed description: Multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of the optimal effective dose of PQ Grass (27600 SU).

Randomized study subjects, in a randomisation ratio of 1:1, will receive either treatment with 6 injections of active treatment (900, 2700, 6000, 6000, 6000 and 6000 SU sequentially) to achieve a cumulative nominal dose of 27600 SU, or 6 injections of placebo prior to the onset of the grass pollen season (GPS).

The aim of the study is to confirm the efficacy and safety of the optimal effective dose of the PQ Grass 27600 SU dose. Efficacy will be determined through the measurements of the effect of PQ Grass on the symptoms of seasonal allergic rhinitis (SAR)/rhinoconjunctivitis and the use of relief medications to control these symptoms during the peak GPS.

Eligibility criteria: Inclusion Criteria:

1. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the ICF (informed consent form) and in this clinical trial protocol and to attend required clinical trial visits.
2. Subject who has a signed and dated ICF.
3. Subject must be 18 to 65 years of age inclusive, at the time of signing the ICF.
4. Male or female.
5. Female subjects who are not of childbearing potential (defined as at least 12 months natural spontaneous amenorrhoea, or at least 6 weeks following surgical menopause/permanent sterilisation \[hysterectomy, bilateral oophorectomy and bilateral salpingectomy\]) or females of childbearing potential who agree to comply with the contraceptive requirements of the clinical trial protocol.
6. Good general health, as determined by the Investigator, based on a medical evaluation, including medical history, physical examination, mental status assessment and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the clinical trial procedures.
7. Positive history of moderate to severe symptoms of SAR/rhinoconjunctivitis ascribed to grass (Pooideae) pollen exposure of at least 2 seasons duration, despite having received allergy pharmacotherapy (e.g., antihistamines, nasal corticosteroids, leukotriene modifiers, etc.) during the last 2 consecutive grass pollen seasons prior to the clinical trial, confirmed by subject records.

   Please note: Subjects with asthma may be included, but the asthma must be well controlled (according to current Global Initiative for Asthma \[GINA\] guidelines \[GINA 2022\]).
8. A positive SPT (skin prick test) to histamine (wheals \[longest diameter\] ≥3 mm) and a negative SPT to the negative control (wheal diameter = 0 mm) at screening.
9. A positive SPT for grass pollen (wheals \[longest diameter\] ≥3 mm).
10. Grass specific IgE (immunoglobulin E) class ≥2 as documented by an ImmunoCAP test at screening.
11. Forced expiratory volume in one second (FEV1) ≥70% of predicted, with a FEV1/forced vital capacity (FVC) ratio \>75% and PEFR (peak expiratory flow rate) ≥70% of predicted at screening.

Exclusion Criteria:

1. Pregnant or lactating subject.
2. Presence of any medical history of moderate to severe allergy symptoms (verified by a positive SPT at screening or positive specific IgE \[≥2\] at screening) to any other seasonal allergen (other than grass) or perennial allergens.

   Exception: Period 1, Period 2 and Period 3 of the entire clinical trial will be conducted outside of the pollen season(s) of concern or perennial allergies are irrelevant due to avoidance measures (e.g., cats and dog allergy). Subjects with mild allergy symptoms (only) to any other allergen apart from grass may be included at the discretion of the Investigator. In countries in Europe where Bermuda grass is present, any medical history of moderate to severe allergy symptoms to Bermuda grass (verified by a positive SPT or positive specific IgE \[Class ≥2\]), will also represent a reason for exclusion as it will not be possible to conduct Period 1, Period 2 and Period 3 of the entire clinical trial outside of Bermuda grass pollen season. Albeit Bermuda grass being commonly defined as a grass, it belongs to the Poaceae family, while the sentence (other than grass) in Exclusion criterion #2 refers to grass of Pooideae subfamily (as defined in Inclusion criterion #7).
3. Subjects at US clinical trial sites in regions where southern grasses (Bahia grass, Bermuda grass or Johnson grass) are the dominant grasses and the main cause of grass allergy symptoms with a positive SPT to any of the 3 grasses (irrespective of the severity of symptoms).
4. Moderate to severe symptoms during the 3 years prior to Visit 1 to any other seasonal or perennial allergen not tested in the SPT done at screening that cannot be avoided during the Period 1 to Period 3 of the clinical trial and the symptoms of which may interfere with administration of treatment and/or impact the data collected.
5. Presence of any medical condition that may reduce the ability to survive a serious allergic reaction.
6. Presence of active systemic autoimmune disorder, systemic autoimmune disorders in remission or active organ specific autoimmune disorder.
7. Presence of active malignant neoplasia, severe cardiovascular disease (e.g., coronary artery disease, cardiac insufficiency, etc.), pulmonary insufficiency, severe psychiatric disorders or primary and secondary immunodeficiencies.
8. History of any other immunological disorder or other diseases (including, but not limited cardiovascular \[including uncontrolled or inadequately controlled hypertension\], gastro-intestinal, hepatic, renal, haematological, neurological, endocrine or pulmonary disease) that in the opinion of the Investigator may pose a safety risk or compromise the interpretation of efficacy of the clinical trial treatment.
9. Presence of severe or poorly controlled or uncontrolled asthma as defined by at least 1 of the following criteria:

   1. Severe asthma (as per the current GINA guidelines \[GINA, 2022\]).
   2. Uncontrolled or poorly controlled asthma as per the current GINA guidelines (GINA, 2022).
   3. Asthma that requires more than a daily dose above 800 μg of inhaled budesonide (or clinically comparable inhaled corticosteroid) as per the current GINA guidelines (GINA, 2022).
   4. History of 2 or more systemic corticosteroid courses within 6 months of screening or Visit 2 or 1 course of systemic corticosteroids within 3 months of screening or Visit 2 to treat asthma.
   5. Prior intubation/mechanical ventilation for asthma.
   6. Emergency room visit or hospitalisation for asthma in the 12 months prior to screening or Visit 2.
   7. Any history of a life-threatening asthma attack.
   8. FEV1 \<70% of predicted or FEV1/FVC ≤75% or PEFR \<70% of predicted with or without controller medications at screening or Visit 2.
10. Presence non-atopic rhinitis and/or rhino-sinusitis (with or without polyps).
11. Presence of nasal polyps and/or chronic sinusitis.
12. Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis.
13. Eye surgery within the past 6 months.
14. Presence of any skin conditions (e.g., skin abnormalities, tattoos etc.), which might interfere with the interpretation of the SPT results.
15. Clinical history of Type I diabetes or poorly controlled Type II diabetes.
16. Moderate to severe upper or lower respiratory infections requiring medication within 14 days before screening (Visit 1) or Visit 2.
17. Presence of acute or chronic infection, fever or inflammation at screening or Visit 2.
18. Clinical history of severe systemic reaction or serious systemic reaction in response to AIT (allergen immunotherapy) in the past.
19. Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis.
20. Clinical history of allergy, hypersensitivity or intolerance to the excipients of the investigational drug/placebo.
21. Clinical history of allergy, hypersensitivity or intolerance to the relief medications (for relief of allergy symptoms during Period 3) provided for use in this clinical trial.
22. Clinical history of hereditary angioedema.
23. Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated such as in subjects with hyperthyroidism, uncontrolled hypertension, cardiac arrhythmias, closed angle glaucoma or subjects taking other sympathomimetics).
24. Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria.
25. Clinical history of drug or alcohol abuse, which, in the Investigator's opinion, could interfere with the subject's ability to participate in the clinical trial.
26. Subjects who have suspicion or symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (as assessed by the Investigator) or who have had unprotected contact with a confirmed case of COVID-19 (coronavirus disease 2019) in the 2 weeks prior to screening or Visit 2 (based on the Investigator's discretion).
27. Subjects who were hospitalised for COVID-19 within 6 months prior to screening or Visit 2.
28. Any history of AIT for grass pollen allergy in the past or history of AIT for any other type of allergy (excluding food allergy) in the past 5 years.
29. Inability to adhere to the washout periods listed in the protocol, with respect to screening and to refrain from using the medications indicated until after Visit 11.
30. Treatment with a preparation containing MPL (monophosphoryl lipid-A) (e.g., Cervarix, Shingrix, Fendrix) within 2 years prior to Visit 1 and until after completion of Visit 11 (with the exception of the investigational drug).
31. Previous history of epinephrine auto-injector use.
32. β-blocker medication (local or systemic, including eye drops) for any indication.
33. Monoamine oxidase inhibitors and tricyclic antidepressants. Please note: Tricyclic antidepressants should be avoided at least 2 weeks prior to screening.
34. Any previous therapy (within the previous 5 years) or current therapy with anti IgE (e.g., omalizumab \[Xolair\]) or anti-interleukins (e.g., mepolizumab).
35. Current or past therapy (within the previous 5 years) with any other immunomodulatory biologics.
36. Unable to refrain from any vaccination (including influenza vaccine and COVID-19 vaccine) during the clinical trial (unless administered \>30 days prior to randomisation).

    Please note: Emergency vaccinations (e.g., tetanus due to injury) can be administered at any time. Booster vaccinations (only) for COVID-19 can be administered during the clinical trial apart from during the treatment period. There should be at least 14 days interval from the last administration of the investigational drug/placebo prior to administration of a COVID-19 booster injection.
37. Participation in a clinical research trial with any investigational drug within 4 weeks of Visit 1 or concomitantly with this clinical trial.

    Please note: The period of exclusion begins at the time of the last visit of the prior clinical research trial. Subjects consented and screened, but not dosed in the prior clinical research trial are not excluded.
38. Personal, financial or other dependent relationship (e.g., employee or immediate relative) with the clinical trial site, Sponsor, Sponsor's representative, or another individual who has access to the clinical trial protocol.
39. Vulnerable subjects or those in judicial or governmental detention, detainment or imprisonment in a public institution.
40. Subjects likely to have prolonged periods of absence (e.g., business or personal travel) during the GPS defined as:

    * Absence of a total of 22 days or more in similar geographical regions (as determined by the Investigator), with no single trip in a similar geographical region exceeding 14 days.
    * Absence of a total of 15 days or more in non-similar geographic regions (as determined by the Investigator), with no single trip in a non-similar geographical region exceeding 7 days.
41. Have changed residence to a different geographical region(s) since the last GPS.

Exception: The old and new residences are in the same or similar geographical region as determined by the Investigator.

Primary outcomes:
measure: Combined Symptom and Medication Score (CSMS) Averaged Over the Peak Grass Pollen Season (GPS)
timeFrame: dSS and dMS are recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then CSMS is adjusted to the Peak GPS, which depends on the GPS start and end dates for each region
Secondary outcomes:
measure: Combined Symptom and Medication Score (CSMS) Averaged Over the Entire (or Truncated) Grass Pollen Season (GPS)
timeFrame: dSS and dMS are recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then CSMS is adjusted to the entire GPS, which depends on the GPS start and end dates for each region
measure: Daily Medication Score (dMS) Component of the CSMS Averaged Over the Peak GPS and Entire (or Truncated) GPS
timeFrame: dMS of the CSMS was recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then dMS is adjusted to the peak or entire GPS
measure: Daily Symptom Score (dSS) Component of the CSMS Averaged Over the Peak GPS and Entire (or Truncated) GPS
timeFrame: dSS of the CSMS was recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then dMS is adjusted to the peak or entire GPS
measure: Average Rhinoconjunctivitis Quality of Life Questionnaire With Standardized Activities (RQLQ(S)) Measured Within the Peak GPS
timeFrame: RQLQ(s) is performed at Visit 2 (wk 2-8), Visit 9 (wk 18-31) and Visit 10 (wk 23-36).
measure: Change in Serum Grass-specific IgG4 (Immunoglobulin G4) From Baseline to Visit 7.
timeFrame: Serum grass-specific IgG4 was measured at Visit 1 (baseline) and Visit 7 (wk 12-25)
measure: Number of Well Days During the Peak GPS
timeFrame: dMS and dSS was recorded daily between Visit 8 (wk 16-29) and Visit 11 (wk 28-41). Then number of well days was calculated during peak GPS.
measure: Frequency, Severity and Relationship of AEs (Adverse Event) to Treatment
timeFrame: From visit 1 (baseline) to last follow-up call (week 46)
measure: Frequency of AEs Leading to Premature Discontinuation From Treatment or Clinical Trial
timeFrame: From visit 1 (baseline) to last follow-up call (week 46)
measure: Frequency of AESI (Adverse Events of Special Interest)
timeFrame: From visit 1 (baseline) to last follow-up call (week 46)
measure: Changes in Serum Chemistry Values (Sodium, Potassium and Chloride) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Serum Chemistry Values (Glucose, Uric Acid, Urea, Phosphorus and Cholesterol) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Serum Chemistry Values ( Calcium, Creatinine and Total Bilirubin) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Serum Chemistry Values (Total Protein and Albumin) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Serum Chemistry Values (Alkaline Phosphatase, Lactate Dehydrogenase, Aspartate Aminotransferase, Alanine Aminotransferase and Gamma-glutamyl Transferase) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Serum Chemistry Values (C-reactive Protein) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Haematology Values (Red Blood Cells) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Hematology Values (White Blood Cells and Platelets) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Change in Hematology Values (Hemoglobin) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Clinical Laboratory Values (Urinalysis: pH) Between Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41).
measure: Clinical Laboratory Values (Urinalysis: Protein, Glucose, Bilirubin, Blood and Leukocytes) at Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Clinical Laboratory Values (Urinalysis: Ketones, Nitrite, Urobilinogen ) at Baseline and Visit 11
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
measure: Changes in Vital Signs (Systolic and Diastolic Blood Pressure) From Baseline to All Treatment Visits
timeFrame: From Visit 1 (baseline) to visit 11 (week 28-41)
Other outcomes:
Locations:
city: Centennial
country: United States
facility: IMMUNOe Research Centers
state: Colorado
city: Denver
country: United States
facility: Velocity Clinical Research Denver
state: Colorado
city: Lexington
country: United States
facility: Allergy Partners of Central Kentucky
state: Kentucky
city: Lexington
country: United States
facility: Allergy and Asthma Associates of Bluegrass
state: Kentucky
city: Louisville
country: United States
facility: Family Allergy Asthma Research Institute
state: Kentucky
city: Owensboro
country: United States
facility: Allergy & Asthma Specialists PSC
state: Kentucky
city: Bangor
country: United States
facility: Northern Light Allergy and Immunology
state: Maine
city: Bangor
country: United States
facility: Paul A. Shapero M.D.
state: Maine
city: White Marsh
country: United States
facility: Chesapeake Clinical Research Inc
state: Maryland
city: Ypsilanti
country: United States
facility: Respiratory Medicine Research Institute of Michigan
state: Michigan
city: Columbia
country: United States
facility: Clinical Research of The Ozarks Inc - Warrensburg
state: Missouri
city: Missoula
country: United States
facility: Montana Medical Research
state: Montana
city: Bellevue
country: United States
facility: Nebraska Medical Research Institute, The Asthma & Allergy Center
state: Nebraska
city: Highland Park
country: United States
facility: Parikh Institute for Research LLC
state: New Jersey
city: Ocean City
country: United States
facility: Atlantic Research Center LLC
state: New Jersey
city: Riverdale
country: United States
facility: Weiss Medical
state: New Jersey
city: Charlotte
country: United States
facility: Allergy Asthma and Immunology Research Institute
state: North Carolina
city: Cincinnati
country: United States
facility: Cincinnati Allergy and Asthma Center
state: Ohio
city: Cincinnati
country: United States
facility: Bernstein Clinical Research Center, LLC
state: Ohio
city: Columbus
country: United States
facility: Optimed Research Ltd
state: Ohio
city: Toledo
country: United States
facility: Toledo Institute of Clinical Research Inc
state: Ohio
city: Oklahoma City
country: United States
facility: Oklahoma Institute of Allergy and Asthma Clinical Research, LLC - CRN - PPDS
state: Oklahoma
city: Grants Pass
country: United States
facility: Velocity Clinical Research, Inc
state: Oregon
city: Medford
country: United States
facility: Velocity Clinical Research - Medford - ERN - PPDS
state: Oregon
city: Portland
country: United States
facility: Northwest Research Center
state: Oregon
city: Blue Bell
country: United States
facility: Allergy & Asthma Specialists
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Allergy and Clinical Immunology Associates
state: Pennsylvania
city: Murray
country: United States
facility: Allergy Associate of Utah
state: Utah
city: Fairfax
country: United States
facility: Lysosomal Rare Disorders Research & Treatment Center
state: Virginia
city: Norfolk
country: United States
facility: Eastern Virginia Medical School
state: Virginia
city: Bellingham
country: United States
facility: Bellingham Asthma Allergy and Immunology Clinic
state: Washington
city: Greenfield
country: United States
facility: Allergy, Asthma & Sinus Center, S.C.
state: Wisconsin
city: Madison
country: United States
facility: University of Wisconsin Clinical Science Center
state: Wisconsin
city: Innsbruck
country: Austria
facility: Medizinische Universitaet Innsbruck - Universitatsklinik fuer Dermatologie, Venerologie und Allergologie
city: Kufstein
country: Austria
facility: Bezirkskrankenhaus Kufstein
city: Wien
country: Austria
facility: Medizinische Universitat Wien (Medical University of Vienna)
city: Wien
country: Austria
facility: Ambulatorium für Allergie und klinische Immunologie AAKI
city: Brno
country: Czechia
facility: Fakultní nemocnice u sv. Anny v Brně
city: Jablonec Nad Nisou
country: Czechia
facility: Alergopraktik, s.r.o.
city: Jihlava
country: Czechia
facility: Alergologie a imunologie MUDr. Hofstetr
city: Ostrava-Hrabuvka
country: Czechia
facility: Alergoimuno s.r.o.
city: Pardubice
country: Czechia
facility: ACREDULA BENEDICTA s.r.o.
city: Plzen
country: Czechia
facility: Fakultní nemocnice Plzeň
city: Trutnov
country: Czechia
facility: MŮJ ALERGOLOG s.r.o.
city: Tábor
country: Czechia
facility: KASMED, s.r.o.
city: České Budějovice
country: Czechia
facility: MUDr. Jana Poloniová - alergologie a klinická imunologie
city: Bamberg
country: Germany
facility: CIMS Studienzentrum Bamberg, GmbH
city: Berlin
country: Germany
facility: Charité - Universitaetsmedizin Berlin Klinik fuer Dermatologie, Venerologie und Allergologie/ Abteilung Allergologie und Immunologie
city: Chemnitz
country: Germany
facility: Praxis Dr. Petra El-Naib
city: Dresden
country: Germany
facility: HNO-Praxis Dr. Udo Schaefer
city: Dresden
country: Germany
facility: Klinische Forschung Dresden GmbH
city: Dresden
country: Germany
facility: Praxis fuer HNO und Allergologie
city: Dresden
country: Germany
facility: Universitaetsklinikum Carl Gustav Carus an der TU Dresden
city: Duesseldorf
country: Germany
facility: RKM740 Hals-Nasen-Ohrenheilkunde
city: Duisburg
country: Germany
facility: HNO-Praxis Dr. Uta Thieme
city: Essen
country: Germany
facility: Gemeinschaftspraxis Ruhr
city: Essen
country: Germany
facility: Medizentrum Essen Borbeck
city: Frankfurt am Main
country: Germany
facility: Medaimun GmbH
city: Goch
country: Germany
facility: medicoKIT GmbH
city: Hamburg
country: Germany
facility: Klinische Forschung Hamburg GmbH
city: Hamburg
country: Germany
facility: Hamburger Institut für Therapieforschung GmbH
city: Hamburg
country: Germany
facility: Velocity Clinical Research Hamburg
city: Heidelberg
country: Germany
facility: Praxis Dres. med. Florian Heimlich und Angelika Witzel-Heimlich
city: Landsberg
country: Germany
facility: HNO-Praxis Landsberg
city: Leipzig
country: Germany
facility: Praxis fuer Pneumologie und Allergologie
city: Marburg
country: Germany
facility: Sektion Rhinologie/Allergologie Klinik fuer HNO-Heilkunde, UKGM - Marburg
city: Memmingen
country: Germany
facility: Beldio Research GmbH
city: Mittweida
country: Germany
facility: Facharztpraxis Dr. med. Jan-Christof Bohn
city: Neu Isenburg
country: Germany
facility: Ballenberger, Freytag, Wenisch Institut fuer klinische Forschung GmbH
city: Neuenhagen
country: Germany
facility: Studienzentrum Maerkisch-Oderland
city: Osnabrück
country: Germany
facility: KliFOs - Klinische Forschung Osnabrueck
city: Saalfeld
country: Germany
facility: Studienzentrum Dr. Sabine Lassmann
city: Schwerin
country: Germany
facility: Klinische Forschung Schwerin GmbH
city: Stuttgart
country: Germany
facility: Klinikum Stuttgart - Krankenhaus Bad Cannstatt (KBC) - Frauenklinik
city: Wallerfing
country: Germany
facility: Dres. med. Josef und Wilma Grosskopf
city: Berettyóújfalu
country: Hungary
facility: Gróf Tisza István Kórház Rendelőintézet MEDIDOCUMENT Kereskedelmi és Szolgáltató Betéti Társaság
city: Budapest
country: Hungary
facility: Clinexpert Kft
city: Budapest
country: Hungary
facility: HiTech Medical Kft.
city: Pécs
country: Hungary
facility: Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar
city: Białystok
country: Poland
facility: Prywatny Gabinet Internistyczno - Alergologiczny
city: Białystok
country: Poland
facility: Allergy Clinic Homeo Medicus
city: Częstochowa
country: Poland
facility: Centrum Medyczne Czestochowa - PRATIA - PPDS
city: Katowice
country: Poland
facility: Centrum Medyczne Pratia Katowice
city: Katowice
country: Poland
facility: Specjalistyczna Praktyka Lekarska dr n. med. Joanna Orlicz-Widawska
city: Kielce
country: Poland
facility: ETG Kielce
city: Kraków
country: Poland
facility: Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o.
city: Kraków
country: Poland
facility: Krakowskie Centrum Medyczne
city: Kraków
country: Poland
facility: Malopolskie Centrum Alergologii
city: Lublin
country: Poland
facility: Clinical Best Solutions Sp. Z O.O. Spółka Komandytowa
city: Poznań
country: Poland
facility: Centrum Alergologii Teresa Hofman Sp. z o.o.
city: Poznań
country: Poland
facility: Specjalistyczna Przychodnia Lekarska ALERGO-MED Sp. z.o.o.
city: Rzeszów
country: Poland
facility: EMED Centrum Uslug Medycznych Ewa Śmiałek
city: Skierniewice
country: Poland
facility: ETG Skierniewice
city: Tarnów
country: Poland
facility: ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z.o.o
city: Tarnów
country: Poland
facility: Specjalistyczne Centrum Medyczne Centermed Sp. z o.o.
city: Warszawa
country: Poland
facility: IRMED Irena Wojciechowska
city: Warszawa
country: Poland
facility: WK Medical Service Sp. z o.o.
city: Wrocław
country: Poland
facility: "ALL-MED" Specjalistyczna Opieka Medyczna, Medyczny Instytut Badawczy
city: Wrocław
country: Poland
facility: Michał Bogacki - DOBROSTAN
city: Zabrze
country: Poland
facility: Niepubliczny Zakład Opieki Zdrowotnej Przychodnia Lekarska Hipokrates Sp. z o.o.
city: Łódź
country: Poland
facility: Uniwersytecki Szpital Kliniczny im. Barlickiego, Poradnia alergologii i chorob pluc
city: Łódź
country: Poland
facility: ETG Łódz
Study officials:
References: